Keyphrases
Biosimilar
100%
Infliximab Biosimilar
80%
Rheumatoid Arthritis
65%
Inflammatory Rheumatic Diseases
62%
DANBIO Registry
61%
Myocardial Infarction
57%
Real Patients
57%
Bleeding
34%
Inflammatory Arthritis
34%
Routine Care
33%
Treatment Retention
33%
Psoriatic Arthritis
32%
Axial Spondyloarthritis (AxSpA)
32%
Nationwide Registry
31%
Clinical Variables
28%
Antithrombotic Therapy
28%
Retrospective Analysis
28%
Adverse Cardiac Events
28%
Machine Learning Models
28%
Nave
28%
P2Y12 Inhibitors
28%
Adalimumab
28%
Randomized Clinical Trial
28%
Comparative Effectiveness
28%
Nationwide Observational Study
28%
Revascularization
28%
Clinical Outcomes
28%
GP2017
28%
Adalimumab Biosimilar
28%
Retention Rate
21%
Medical Therapy
20%
CT-P13
17%
Aspirin
17%
Vitamin K Antagonists
14%
Coronary Artery Bypass Grafting
11%
Disease Activity
11%
Low Disease Activity
11%
Clopidogrel
10%
Denmark
10%
Observational Cohort Study
10%
Remission Rate
9%
Myocardial Infarction Patients
9%
Comorbidity
8%
Percutaneous Coronary Intervention
8%
Bleeding Events
7%
Cox Proportional Hazards Model
6%
Biosimilar Infliximab
5%
Non-medical Switching
5%
Successful Uptake
5%
Infliximab
5%
Medicine and Dentistry
Rheumatic Disease
57%
Biosimilar
57%
Observational Study
32%
Rheumatoid Arthritis
31%
Myocardial Infarction
28%
Revascularization
28%
Adalimumab
28%
Infliximab
28%
Combination Therapy
28%
Randomized Clinical Trial
28%
Spondylarthritis
22%
Psoriatic Arthritis
22%
Coronary Artery Bypass Graft
16%
Disease Activity
14%
Proportional Hazards Model
13%
Percutaneous Coronary Intervention
12%
Spontaneous Remission
11%
Logistic Regression Analysis
9%
Cohort Study
9%
Cerebrovascular Disease
8%
Antithrombotic
8%
Bleeding
8%
Ticagrelor
8%
Excipient
5%
Adverse Event
5%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Infarction
57%
Anticoagulant Agent
36%
Major Adverse Cardiac Event
28%
Combination Therapy
28%
Ciclonicate
23%
Acetylsalicylic Acid
23%
Bleeding
22%
Antivitamin K
19%
Clopidogrel
14%
Comorbidity
12%
Antithrombotic Therapy
9%
Cerebrovascular Disease
8%
Ticagrelor
8%